Leflunomide Arrow (Leflunomide)

Leflunomide is converted in the body to teriflunomide, which selectively blocks the enzyme dihydroorotate dehydrogenase. This inhibition curtails de novo pyrimidine synthesis, limiting the proliferation of activated T‑ and B‑lymphocytes and thereby dampening the autoimmune inflammatory response that drives joint damage.

The dosing regimen for leflunomide is individualized by the prescribing healthcare professional based on the patient’s clinical condition, disease severity, and laboratory parameters. Physicians typically start with a loading dose followed by a maintenance dose, but exact amounts should only be set by the prescriber.

Leflunomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women and should not be used by women who may become pregnant. It is also not recommended during breastfeeding because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Leflunomide Arrow. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

The most common alternative DMARD is methotrexate. While both suppress immune activity, leflunomide primarily inhibits pyrimidine synthesis, whereas methotrexate interferes with folate metabolism. Leflunomide may be preferred when patients cannot tolerate methotrexate’s hepatic or gastrointestinal side effects, but both require regular monitoring.

Leflunomide Arrow tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and ensure the packaging is tightly closed to maintain product stability.

Leflunomide Arrow is administered orally as a tablet. Patients should swallow the tablet whole with a full glass of water, preferably with food to minimize gastrointestinal discomfort. The exact timing and any dose adjustments are determined by the prescribing clinician.

The most serious adverse events include severe liver injury (hepatitis or hepatic failure), hematologic abnormalities such as leukopenia, anemia, or thrombocytopenia, and pulmonary toxicity like interstitial lung disease. Patients should report symptoms such as jaundice, unusual bruising, persistent cough, or shortness of breath immediately.

Leflunomide Arrow should not be used by pregnant women, individuals with severe hepatic impairment, patients with active serious infections, or those with known hypersensitivity to leflunomide or its excipients. Caution is also advised for patients with compromised immune systems or pre‑existing lung disease.